News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,746 Results
Type
Article (13949)
Company Profile (304)
Press Release (247493)
Section
Business (79363)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50331)
Employer Resources (32)
FDA (5682)
Job Trends (5116)
News (144145)
Policy (10018)
Tag
Academia (901)
Alliances (21526)
Alzheimer's disease (758)
Approvals (5665)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (889)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40139)
Collaboration (310)
Compensation (129)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (67)
Data (984)
Diabetes (87)
Diagnostics (1207)
Drug discovery (57)
Earnings (29007)
Events (47193)
Executive appointments (247)
FDA (6054)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1065)
Healthcare (6543)
Infectious disease (1044)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2559)
Medtech (2560)
Mergers & acquisitions (6128)
Metabolic disorders (260)
Neuroscience (1001)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1092)
Obesity (140)
Opinion (91)
Parkinson's disease (76)
Patents (61)
People (25109)
Phase I (14151)
Phase II (18664)
Phase III (11819)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (202)
Real estate (1409)
Regulatory (8289)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8669)
Vaccines (165)
Weight loss (84)
Date
Today (22)
Last 7 days (362)
Last 30 days (1395)
Last 365 days (20550)
2024 (20462)
2023 (22416)
2022 (26822)
2021 (27805)
2020 (23361)
2019 (16226)
2018 (11739)
2017 (13745)
2016 (11840)
2015 (14350)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (146)
Asia (16924)
Australia (2856)
California (2475)
Canada (809)
China (204)
Colorado (91)
Connecticut (104)
Europe (36449)
Florida (272)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (331)
Massachusetts (1957)
Michigan (56)
Minnesota (101)
New Jersey (631)
New York (684)
North Carolina (419)
Northern California (1092)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (279)
Washington State (248)
261,746 Results for "anika therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Pendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal, Monovisc, and Orthovisc
Pendopharm is pleased to announce the renewal of its exclusive distribution agreement with Anika Therapeutics Inc (NASDAQ: ANIK) (Anika) for Cingal ® , Monovisc ® and Orthovisc ® through the end of 2030.
May 16, 2024
·
2 min read
Press Releases
Anika To Participate in December 2024 Investor Conferences
November 25, 2024
·
2 min read
Genetown
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on June 3, 2024, Anika granted: non-statutory stock options covering 96,525 shares of common stock at a per share exercise price of $29.35.
June 7, 2024
·
2 min read
Business
Anika Reports First Quarter 2024 Financial Results
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its first quarter ended March 31, 2024.
May 8, 2024
·
14 min read
Press Releases
Anika Reports Third Quarter 2024 Financial Results
November 1, 2024
·
20 min read
Business
Anika Announces CFO Transition - May 08, 2024
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024.
May 8, 2024
·
6 min read
Business
Anika Announces Third Quarter 2024 Results Conference Call Date
October 17, 2024
·
1 min read
Genetown
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Anika Therapeutics, Inc. today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024.
April 2, 2024
·
1 min read
Press Releases
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
November 1, 2024
·
6 min read
Genetown
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
Anika Therapeutics, Inc. announced that on May 1, 2024, Anika granted non-statutory stock options covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee.
May 3, 2024
·
2 min read
1 of 26,175
Next
